Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: Data from the GUSTO-III Trial

Williams, Eric S.; Thompson, Vivian; Chiswell, Karen; Alexander, John H.; White, Harvey D.; Ohman, E. Magnus; Al‐Khatib, Sana M.

doi:10.5603/cj.2013.0104

Cited by 11 publications

(7 citation statements)

References 23 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 14 A prospective study of patients with new‐onset AF post‐ACS in the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries)‐III trial found that rhythm control in those with CrCl less than 60 ml/min was associated with lower odds of sinus rhythm at discharge compared to their counterparts. 15 Nevertheless, this was not statistically significant after adjusting for other risk factors.…”

Section: Discussionmentioning

confidence: 84%

“…Schmidt et al found that patients with an eGFR below 60 ml/min had significantly increased risk of AF recurrence at 1‐month following cardioversion 14 . A prospective study of patients with new‐onset AF post‐ACS in the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries)‐III trial found that rhythm control in those with CrCl less than 60 ml/min was associated with lower odds of sinus rhythm at discharge compared to their counterparts 15 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry

Ding

Potpara

Blomström‐Lundqvist

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry

Ding

Potpara

Blomström‐Lundqvist

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Currently, ESC guidelines [1] recommend that rhythm control therapy is indicated to improve symptoms in AF patients who remain symptomatic on adequate rate control therapy. To date, there is a lack of studies on AF management in the acute phase of myocardial infarction, and little is known about the impact of AF treatment strategy on clinical outcomes in these patients [31][32][33].…”

Section: Management: Anticoagulation and Rhythm Controlmentioning

confidence: 99%

De novo atrial fibrillation as an independent prognostic marker after ST-segment elevation myocardial infarction: Results from the RIMA registry

Gourronc

Grall

Ingremeau

et al. 2019

Journal of Cardiology

View full text Add to dashboard Cite

Background: Atrial fibrillation (AF) is common in ST-segment elevation myocardial infarction (STEMI), but its influence on prognosis remains controversial. Aim: We examined the 1-year prognostic value of AF in STEMI, distinguishing patients with prior AF from patients with de novo AF. Methods: Between January 2004 and December 2015, 3173 STEMI patients were enrolled in the RIMA registry (Registre des Infarctus en Maine Anjou). They were divided into 3 groups: (1) AF-free patients; (2) patients with known prior AF; and (3) patients with de novo AF during hospitalization (including admission). We defined 3 primary outcomes at 1-year post-discharge: cardiovascular mortality, readmission for heart failure (HF), and stroke. Temporal onset of de novo AF was also studied. Results: A total 158 patients (5%) had prior AF, and 278 (8.8%) presented de novo AF. Prior AF patients were significantly older [81 (73;86) years] with more comorbidities, but de novo AF patients presented with a greater creatine kinase peak and lower left ventricular ejection fraction [LVEF = 44 (35;50)% for de novo AF vs 50 (40;55)% for prior AF, p < 0.001]. At 1-year follow-up, cardiovascular mortality was higher in cases of AF (13.5% for prior AF vs 9.2% for de novo AF, compared with 2.4% for AF-free patients, p < 0.001). After adjustments, only de novo AF was correlated with cardiovascular mortality (hazard ratio 2.49; 95% CI 1.32-4.67; p = 0.004), but both types of AF were correlated with readmission for HF. There was no significant difference in respect of stroke between prior AF, de novo AF, and AF-free (2.2%, 0.5%, and 0.8%, respectively, p = 0.327). Finally, outcomes did not differ between AF occurring <24 h after admission (n = 127) and de novo AF occurring within !24 h (n = 151). Conclusion: De novo AF was independently associated with 1-year cardiovascular mortality. It should not be considered as an intercurrent event of STEMI, but rather as a strong prognostic marker.

show abstract

“…In a post hoc analysis of the GUSTO III trial, treatment with a rhythm or rate control strategy did not significantly impact short-or long-term mortality regardless of kidney disease status. 100…”

Section: Rate Vs Rhythm Control Of Atrial Fibrillationmentioning

confidence: 99%

Chronic Kidney Disease and Arrhythmias: Conclusions From a Kidney Disease: Improving Global Outcomes (Kdigo) Controversies Conference

Carrero

Clase

Deo

et al. 2019

Nefrologiâ (St.-Peterbg.)

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders, including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular arrhythmias, and sudden cardiac death (SCD). While treatment options, including drug, device, and procedural therapies, are available, their use in the setting of CKD is complex and limited. Patients with CKD and end-stage kidney disease have historically been under-represented or excluded from randomized trials of arrhythmia treatment strategies, 1 although this situation is changing. Cardiovascular society consensus documents have recently identified evidence gaps for treating patients with CKD and heart rhythm disorders. To identify key issues relevant to the optimal prevention, management, and treatment of arrhythmias and their complications in patients with kidney disease, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference in Berlin, Germany, titled CKD and Arrhythmias in October 2016.

show abstract

Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: Data from the GUSTO-III Trial

Abstract: (unadjusted OR 0.56, p < 0.001). However, in multivariable analyses, treatment with a rhythm control strategy was not associated with discharge rhythm (HR 1.068, p = 0.77), p = 0.18) or mortality from day 30 to 1 year (HR 1.00, p = 0.99 (Cardiol J 2013; 20, 4: 439-446)

Cited by 11 publications

References 23 publications

Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry

Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry

De novo atrial fibrillation as an independent prognostic marker after ST-segment elevation myocardial infarction: Results from the RIMA registry

Chronic Kidney Disease and Arrhythmias: Conclusions From a Kidney Disease: Improving Global Outcomes (Kdigo) Controversies Conference

Contact Info

Product

Resources

About